HSCT no better than chemo in Philadelphia-negative acute lymphoblastic leukemia

HSCT no better than chemo in philadelphia-negative ALL

(HealthDay)—For patients ≥40 years of age with Philadelphia (Ph)-negative acute lymphoblastic leukemia (ALL), hematopoietic stem-cell transplantation (HSCT) in first remission is associated with lower cumulative incidence of relapse (CIR), but worse non-relapse mortality (NRM), compared with chemotherapy alone, according to a study published online May 6 in the American Journal of Hematology.

Ofir Wolach, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues examined whether HSCT in first remission confers a survival benefit versus chemotherapy alone in patients ≥40 years of age with Ph-negative ALL. The outcome of patients treated with HSCT or chemotherapy alone in first remission (40 patients in each cohort) was compared.

The researchers observed no significant difference in three-year overall survival (OS) and disease-free survival (DFS) between the chemotherapy alone and HSCT groups (OS, 46 versus 40 percent; P = 0.35; DFS, 31 versus 40 percent; P = 0.98). The three-year CIR was 61 and 28 percent for the chemotherapy-only and HSCT groups, respectively (P = 0.011), while three-year NRM was 9 and 32 percent, respectively (P = 0.014).

"Allogeneic transplantation for patients ≥40 years with Ph-negative ALL in first is associated with a lower CIR but this benefit is offset by considerable NRM as compared with -only approach," the authors write. "HSCT may be beneficial in with high-risk disease features."

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: American Journal of Hematology

Copyright © 2016 HealthDay. All rights reserved.

Citation: HSCT no better than chemo in Philadelphia-negative acute lymphoblastic leukemia (2016, June 3) retrieved 8 December 2023 from https://medicalxpress.com/news/2016-06-hsct-chemo-philadelphia-negative-acute-lymphoblastic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Donor epstein-barr serostatus influences GVHD after allo-HSCT


Feedback to editors